Fiera Capital Corp acquired a new stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) in the fourth quarter, HoldingsChannel reports. The firm acquired 874,053 shares of the company’s stock, valued at approximately $33,398,000.
A number of other institutional investors have also recently made changes to their positions in the company. Raymond James Financial Inc. bought a new stake in Travere Therapeutics during the second quarter worth approximately $33,000. State of Wyoming purchased a new position in shares of Travere Therapeutics in the 4th quarter worth approximately $37,000. Torren Management LLC bought a new position in shares of Travere Therapeutics during the 4th quarter valued at approximately $38,000. Comerica Bank raised its holdings in Travere Therapeutics by 77.5% during the 4th quarter. Comerica Bank now owns 1,127 shares of the company’s stock valued at $43,000 after buying an additional 492 shares during the period. Finally, Garner Asset Management Corp purchased a new stake in Travere Therapeutics during the 4th quarter valued at $69,000.
Travere Therapeutics Stock Up 2.8%
Shares of NASDAQ TVTX opened at $47.08 on Tuesday. Travere Therapeutics, Inc. has a 52-week low of $13.88 and a 52-week high of $48.61. The firm has a market capitalization of $4.38 billion, a price-to-earnings ratio of -204.69 and a beta of 1.13. The stock has a 50 day moving average price of $40.10 and a 200 day moving average price of $34.86. The company has a debt-to-equity ratio of 3.16, a quick ratio of 3.08 and a current ratio of 3.13.
Analysts Set New Price Targets
A number of brokerages recently issued reports on TVTX. HC Wainwright raised their price target on Travere Therapeutics from $57.00 to $67.00 and gave the stock a “buy” rating in a research report on Tuesday, June 2nd. Wall Street Zen downgraded shares of Travere Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Wells Fargo & Company raised their target price on shares of Travere Therapeutics from $40.00 to $50.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Guggenheim lifted their price target on shares of Travere Therapeutics from $54.00 to $56.00 and gave the stock a “buy” rating in a research note on Friday, April 24th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Travere Therapeutics from $44.00 to $41.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 25th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Travere Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $48.92.
Read Our Latest Analysis on TVTX
Insider Buying and Selling at Travere Therapeutics
In other Travere Therapeutics news, insider Elizabeth E. Reed sold 2,076 shares of Travere Therapeutics stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $43.95, for a total transaction of $91,240.20. Following the completion of the sale, the insider directly owned 105,211 shares of the company’s stock, valued at $4,624,023.45. The trade was a 1.93% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Eric M. Dube sold 22,500 shares of the company’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $43.95, for a total transaction of $988,875.00. Following the completion of the sale, the chief executive officer directly owned 432,886 shares of the company’s stock, valued at approximately $19,025,339.70. This trade represents a 4.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 400,015 shares of company stock worth $15,895,428 over the last quarter. Insiders own 4.44% of the company’s stock.
About Travere Therapeutics
Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.
The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.
Read More
- Five stocks we like better than Travere Therapeutics
- 3 Stocks With Fresh Catalysts to Watch Before the July 4
- Amprius Insiders Are Selling: Should Investors Be Worried?
- A Weaker Dollar Could Put These 3 Industrial Stocks Back in Focus
- A Market Rotation Toward Quality Will Benefit These 3 ETFs
Want to see what other hedge funds are holding TVTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report).
Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
